Economists around the world expect muted U.S. economic growth in the coming quarters, and some indicators have shown an increased likelihood of a 2025 recession in recent weeks. [ Sign up for ...

Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expect ...

Detailed price information for Harvest Eli Lilly Enhanced High Income S (LLHE-T) from The Globe and Mail including charting and trades.

The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.

PALM BEACH, Fla., March 10, 2025 (GLOBE NEWSWIRE) -- FN media Group News Commentary - A report from Fortune Business Insights said that the global artificial intelligence in healthcare market size is ...

Despite reporting positive Phase II results for its lead candidate last year, Vaccinex will soon no longer be a publicly ...

Palm Beach, FL – March 10, 2025 – A report from Fortune Business Insights said that the global artificial intelligence in healthcare market size is projected to grow from USD 27.69 billion in 2024 to ...

All three stocks let their investors down last week, but the catalysts are there for all three names to turn things around.

Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.

Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to eMarketer. Obesity drugs have also started showing up in emp ...

Eli Lilly is investing $27 billion in U.S. manufacturing to expand drug production and secure future supply. The company will ...

Eli Lilly remains a favorite among billionaires, ranking 11th in top stock picks. The pharmaceutical giant’s 2024 revenue ...